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DOI: http://dx.doi.org/10.1016/j.hemonc.2013.09.004A 31-year-old male patient presented with fever and pancytopenia. He was diagnosed as a case of chronic
anemia since early childhood. The etiology of the anemia was not known. The patient was transfusion
dependent, and he had been maintained on erythropoietin for three years prior to admission. A bone
marrow examination revealed prominent proliferation of immature and dysplastic erythroid precursors.
Acute erythroid leukemia of the pure erythroid subtype was suspected. However, because of the history
of erythropoietin therapy a definite diagnosis was not made. On follow-up one month later, the marrow
changes had reversed to normal.CASEA31-year-old male patient was diagnosed andfollowed up as a case of chronic anemia by aprivate hematologist since early childhood
years. The etiology of his anemia was never found de-
spite extensive testing. His anemia was clinically char-
acterized as being hemolytic with high serum lactate
dehydrogenase (LDH) and indirect bilirubin and with
splenomegaly. Testing for osmotic fragility of RBCs,
G6PD and direct antiglobulin test (DAT) was made,
among other tests. Molecular testing for alpha and
beta thalassemia was negative and his marrow was
hypercellular. He was maintained on corticosteroids.
For three years prior to admission, the patient had
also been maintained on erythropoietin which,
according to his hematologist, decreased transfusion
requirements and dependency. One week prior to
admission, the patient developed fever and respiratory
tract-like illness for which a presumptive diagnosis of
pulmonary infection was made. He was found to have
pancytopenia with the following counts:
WBC: 3.1 · 109/L; RBC: 2.43 · 1012/L; Hemo-
globin: 8.7 g/dL; Hematocrit: 25.5%; Platelets:
46 · 109/L.
A bone marrow aspirate and trephine biopsy were
performed.HeThe aspirate revealed hypercellular particles that
were almost totally replaced by early proerythroblasts
with megaloblastoid maturation and dyserythropoiesis
including binuclear and trinuclear forms with
cytoplasmic vacuolation (Figure 1). The periodic
acid-Schiff (PAS) stain showed block positivity in
proerythroblasts (Figure 2). Rare granulocytic
precursors were present. Occasional histiocytes with
erythrophagocytosis were identiﬁed. Stainable iron
was markedly increased. No ringed sideroblasts were
identiﬁed.
The biopsy was hypercellular for age with 100%
cellularity. Erythroid precursors were quantitatively
markedly increased with predominant proerythroblast
stage (Figure 3). Granulocytic precursors were
quantitatively decreased and megakaryocytes were
slightly decreased. Minor marrow populations,
lymphocytes and plasma cells were not increased.
Reticulin stain showed grade II/IV reticulin ﬁbrosis.
The ﬁndings were so impressive that in conjunc-
tion with the pancytopenia, the possibility of acute
erythroid leukemia of the pure erythroid subtype
was considered. However, according to the 2008
World Health Organization (WHO) classiﬁcation
of tumors of the hematopoietic and lymphoid tissues,1
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Figure 1. Almost exclusive population of proerythroblasts with cytoplasmic vacuoles.
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for a repeat bone marrow examination in one month.
The repeat examination showed normalization of the
components of the marrow with reversal of the M:E
ratio (Figure 4).Figure 2. PAS stain shows block-like cytoplasmic positivity in the
proerythroblasts (center).
Figure 3. Hypercellular trephine biopsy with predominance of
erythroblasts.
Figure 4. Follow-up biopsy showed normalization of the marrowDISCUSSION
Acute erythroid leukemia is amongst the rarest types
of acute myeloid leukemia.2 The last edition of the
WHO classiﬁcation of tumours of hematopoietic
and lymphoid tissues recognizes two types of ery-
throid leukemia: erythroleukemia (erythroid/myeloid)
and pure erythroid leukemia.2 Erythroleukemia is de-
ﬁned by the presence of 50% or more erythroid pre-
cursors of the entire nucleated cell population and
20% or more myeloblasts of the non-erythroid cells.
Pure erythroid leukemia is a neoplastic proliferation
of immature cells committed exclusively to erythroid
lineage representing 80% or more of the marrow cells
with no signiﬁcant myeloblasts. Common presenta-
tions are profound anemia and circulating erythro-
blasts. The erythroid neoplastic cells show dysplastic
changes represented by bi- or multi-nucleation; meg-
aloblastoid nuclei and the cytoplasm frequently con-
tain poorly demarcated vacuoles that can coalesce.
Ring sideroblasts and PAS positivity can be seen.
Neutrophilic and megakaryocytic dysplasia are fre-
quent. The marrow is usually hypercellular. Hemo-
phagocytic lymphohistiocytosis (HLH) has been
described in association with erythroid leukemia.3
The differential diagnosis of acute erythroid leuke-
mia is broad, and includes both non-neoplastic and
neoplastic conditions. Among the non-neoplastic
causes of erythroid hyperplasia, vitamin B12/folate
deﬁciency and previous erythropoietin treatment need
to be considered. Other less common non-neoplastic
causes of reactive erythroid hyperplasia include toxin
exposure, especially benzene, congenital dyserythro-
poiesis and Parvovirus infection.4components and the M:E ratio.
Hematol Oncol Stem Cell Ther 7(1) First Quarter 2014 hemoncstem.edmgr.com 51
52
case report ERYTHROPOIETIN-INDUCED ACUTE ERYTHROID LEUKEMIA-LIKE PICTURE
The diagnosis of acute erythroid leukemia of the
pure erythroid type has been problematic. Prior to
the last edition of the WHO classiﬁcation,1 which
clearly identiﬁed erythropoietin as a cause of benign
reactive erythropoiesis that mimics pure erythroid leu-
kemia, many of the cases diagnosed as deﬁnite or sus-
picious of primary erythroid leukemia were
retrospectively re-diagnosed as benign reactive ery-
throid hyperplasia. Zuo et al, for example, reviewed
a number of cases which showed predominant popu-
lation of erythroid precursors and were either diag-
nosed as acute erythroid leukemia or suggestive of
acute erythroid leukemia at the University of Texas
M.D. Anderson Cancer Center.5 The authors identi-
ﬁed a group of cases with previous history of erythro-
poietin administration, questioning the diagnosis in
such cases, and considering prior erythropoietin treat-
ment as an exclusion criterion for the diagnosis. The
current WHO blue book does not list erythropoietin
treatment as an absolute exclusion criterion, though
the book mentions erythropoietin treatment in the
differential diagnosis of pure erythroid leukemia.1HeIn their review article, Zuo et al. state that, in their
experience, the most common cause of a marrow that
contains 50% or more erythroid precursor is erythro-
poietin treatment.6 This highlights the importance of
excluding a history of erythropoietin treatment in
such case scenarios. Furthermore, erythropoietin ther-
apy, by means of increasing the erythroid precursors
in the bone marrow, makes the estimation of blast
count much more difﬁcult.7 One of the most impor-
tant differentiating points between erythropoietin-in-
duced erythroid hyperplasia and pure erythroid
leukemia, in addition to history of erythropoietin
treatment, is that pure erythroid leukemia presents
as anemia or pancytopenia, while patients on erythro-
poietin treatment usually show improvement of their
pr-existing anemia in response to the treatment.CONFLICT OF INTEREST
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